Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | 1 | 1 | 1 | — | — | 2 |
Transitional cell carcinoma | D002295 | — | — | 1 | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 5 | 2 | — | — | — | 7 |
Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | 1 | — | — | — | 1 |
Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
Non-muscle invasive bladder neoplasms | D000093284 | — | — | — | 1 | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 1 | — | — | — | 1 |
Squamous cell neoplasms | D018307 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Urologic neoplasms | D014571 | — | C64-C68 | 1 | — | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Rogaratinib |
INN | rogaratinib |
Description | Rogaratinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target fibroblast growth factor receptor 1 and fibroblast growth factor receptor 3. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COCc1c(-c2cc3cc(C)cc(OC)c3s2)c2c(N)ncnn2c1CN1CCNC(=O)C1 |
PDB | — |
CAS-ID | 1443530-05-9 |
RxCUI | — |
ChEMBL ID | CHEMBL3963485 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 98BSN6N516 (ChemIDplus, GSRS) |